Using ETBF lysate as coating antigen, it was ascertained that 38 (38/39, 97%) of the CRC cases had anti-ETBF IgG antibodies above the cut-off, while all (39/39, 100%) of the cases had anti-ETBF IgA antibodies above the cut-off. This evidence concerns the gene CD79A and colorectal carcinoma.